Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells.
暂无分享,去创建一个
Ying-Xuan Chen | Xiao-qing Tian | Yan-jie Zhang | H. Xiong | Qin-Chuan Liang | Yingxuan Chen | Jing-Yuan Fang | Rong Lu | Hua Xiong | Zhi-Gang Zhang | Xiao-Qing Tian | Dan-Feng Sun | Qin-Chuan Liang | Yan-Jie Zhang | Rong Lu | Zhi-gang Zhang | J. Fang | Dan‐feng Sun
[1] Prahlad T. Ram,et al. Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L Galphao protein. , 2000, Science.
[2] H. Allgayer,et al. Analysis of Specific Transcriptional Regulators as Early Predictors of Independent Prognostic Relevance in Resected Colorectal Cancer , 2007, Clinical Cancer Research.
[3] Jingwen Liu,et al. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells , 2003, Oncogene.
[4] A. Walch,et al. STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation , 2006, Journal of Clinical Pathology.
[5] D. Frank,et al. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas , 2007, Oncogene.
[6] R Nyga,et al. The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation , 2007, Oncogene.
[7] F. Ciardiello,et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer , 2007, Oncogene.
[8] Hans C Clevers,et al. Molecular causes of colon cancer , 2002, European journal of clinical investigation.
[9] Kenichi Matsubara,et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma , 2005, Oncogene.
[10] Shan Wang,et al. Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. , 2004, World journal of gastroenterology.
[11] D. Levy,et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death , 2002, Oncogene.
[12] J. Darnell,et al. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[13] S. Brand,et al. Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease , 2007, Gut.
[14] W. Klapper,et al. High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma , 2007, Leukemia.
[15] Z. Yi,et al. Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-kappaB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis. , 2007, Blood.
[16] Li Li,et al. Autocrine-mediated Activation of STAT3 Correlates with Cell Proliferation in Breast Carcinoma Lines* , 2002, The Journal of Biological Chemistry.
[17] Jing-Yuan Fang,et al. Inhibition of the Extracellular Signal-regulated Kinase/Mitogen-activated Protein Kinase Pathway Decreases DNA Methylation in Colon Cancer Cells* , 2007, Journal of Biological Chemistry.
[18] P. Dent,et al. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. , 2005, Molecular cancer therapeutics.
[19] Toshiyuki Nakayama,et al. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. , 2006, Oncology reports.
[20] Lothar Schweigerer,et al. Hepatocyte Growth Factor/c-Met Signaling Promotes the Progression of Experimental Human Neuroblastomas , 2004, Cancer Research.
[21] S. Fan,et al. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. , 2000, Annals of surgery.
[22] J. Darnell,et al. Stat3 as an Oncogene , 1999, Cell.
[23] G. Feldman,et al. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.
[24] J. Pober,et al. Interleukin-11 Up-Regulates Survivin Expression in Endothelial Cells through a Signal Transducer and Activator of Transcription-3 Pathway , 2001, Laboratory Investigation.
[25] S. Nagata,et al. Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[26] G. Milano,et al. JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. , 2006, European journal of cancer.
[27] R. Jove,et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.
[28] T. Nagayasu,et al. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors , 2005, Journal of Clinical Pathology.
[29] Sanjeev Banerjee,et al. Regression of early and intermediate stages of colon cancer by targeting multiple members of the EGFR family with EGFR-related protein. , 2007, Cancer research.
[30] A. Mottok,et al. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. , 2007, Blood.
[31] R. Jove,et al. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] J. Pow-Sang,et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.
[33] J. Turkson,et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. , 2003, Cancer research.
[34] Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. , 2007, Gut.
[35] Didier Merlin,et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. , 2007, Cancer research.
[36] Y. Miyagi,et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. , 2007, Cancer research.
[37] R Berger,et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.
[38] M. Fornaro,et al. Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor-α-induced Apoptosis via the AKT/Survivin Pathway* , 2003, Journal of Biological Chemistry.
[39] Simon C Watkins,et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[40] S. Curran,et al. Profiling markers of prognosis in colorectal cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] T. Toyama,et al. Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells , 2003, Oncogene.
[42] D. Neri,et al. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. , 2007, Cancer research.
[43] T. Chiba,et al. Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway , 2003, Oncogene.
[44] M. Meyerson,et al. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. , 2006, Cancer research.
[45] Guoqiang Chen,et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[46] T. McDonnell,et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma , 2003, Oncogene.